Last reviewed · How we verify
NDI-034858
At a glance
| Generic name | NDI-034858 |
|---|---|
| Also known as | TAK-279 |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis (PHASE3)
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines (PHASE3)
- A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis (PHASE3)
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines (PHASE3)
- A Study of Zasocitinib in Adults With Hidradenitis Suppurativa (PHASE2)
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis (PHASE2)
- Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NDI-034858 CI brief — competitive landscape report
- NDI-034858 updates RSS · CI watch RSS
- Takeda portfolio CI